Digestive Cancer

The information below is intended for use by health care providers only. Please consult with your health care provider for more information about clinical trials.

AHPBA Registry Database

The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.

Study Details

  • Study Site/Tumor Location: Pancreatic
  • Study Location: Miami Valley Hospital
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Jim Ouellette

Study Contact Information

Circulating tumor DNA exposure in peripheral blood using a novel process: A feasibility study

The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the detection of circulating tumor DNA (ctDNA).

Study Details

  • Study Site/Tumor Location: Colon or rectal, pancreatic, gastric, or hepatocellular carcinoma hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma
  • Study Location: Miami Valley Hospital
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Jim Ouellette

Study Contact Information

EA2142 Cisplatin & Etoposide Vs. Temozolomide & Capecitabine Advanced G3 NSC Gastroenteropancreatic Neuroendocrine Ca.

Study Details

  • Study Site/Tumor Location: Pancreatic
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC

This is a Phase 3, randomized, open-label, multicenter, global study designed to compare the efficacy and safety of BGB-A317 versus sorafenib as a first-line systemic treatment in patients with unresectable hepatocellular carcinoma. This study also includes a substudy investigating the safety, tolerability, PK, and preliminary efficacy in HCC in Japanese patients. In Japan, preliminary safety and tolerability will be evaluated (Safety Run-In Substudy) before Japanese patients are recruited in this Phase 3 study.

Study Details

  • Study Site/Tumor Location: Hepatocellular Carcinoma
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Bane
  • Other Physicians who can consent: Kathula, Shah, Yanes

Study Contact Information

S1815 Gemcitabine, Cisplatin, and Nab-Paclitaxel Vs Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers

Study Details

  • Study Site/Tumor Location: Pancreatic
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information